- Home
- CNTA vs ADNT Comparison
CNTA vs ADNT Comparison
Compare CNTA & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTA | ADNT |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United Kingdom | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 1.7B |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CNTA | ADNT |
|---|---|---|
| Price | $39.71 | $20.29 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 11 |
| Target Price | ★ $42.00 | $25.32 |
| AVG Volume (30 Days) | ★ 3.8M | 818.6K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $15,000,000.00 | ★ $17,439,000,000.00 |
| Revenue This Year | N/A | $2.75 |
| Revenue Next Year | N/A | $2.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.56 |
| 52 Week Low | $9.60 | $10.04 |
| 52 Week High | $40.26 | $27.32 |
Technical Indicators
Market Signals| Indicator | CNTA | ADNT |
|---|---|---|
| Relative Strength Index (RSI) | 77.43 | 44.63 |
| Support Level | $22.49 | $18.59 |
| Resistance Level | N/A | $23.87 |
| Average True Range (ATR) | 1.56 | 0.73 |
| MACD | 1.29 | 0.10 |
| Stochastic Oscillator | 96.22 | 48.87 |
Price Performance
Historical ComparisonAbout CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.